Program - Society of Toxicology

Society of Toxicology 2011
Continuing Education (Continued)
• Evaluating Epigenetic Changes Using Bisulfite Deep Sequencing,
Russell S. Thomas, The Hamner Institutes for Health Sciences,
Research Triangle Park, NC
• Population-Based DNA Methylation Profiling in Exposure-Related
Disease, Carmen Marsit, Brown University, Providence, RI
Sunday Afternoon, March 6
1:15 PM to 5:00 PM
First and Second Level (See signage at CE Booths for room
locations)
Toxicity Testing: State of Science and Strategies to
Improve Public Health
Quantitative In Vitro to In Vivo Extrapolation: The Essential
Element of In Vitro Assay-Based Risk Assessment
PM13
CE Basic
Chairperson(s): Harvey J. Clewell, III, The Hamner Institutes for Health
Sciences, Research Triangle Park, NC, and Bastiaan Johan Blaauboer,
Utrecht University, Utrecht, Netherlands.
Sponsor:
Risk Assessment Specialty Section
Endorsed by:
Biological Modeling Specialty Section
In Vitro and Alternative Methods Specialty Section
Nanotoxicology Specialty Section
There is increasing recognition of the need to use efficient approaches to
assess the risk assessment of high numbers of chemicals in a short time.
The reliance on approaches consisting of animal experimentation has its
drawbacks in terms of ethical, economical, and—not least—scientific
limitations in assessing risks in a high-throughput mode. The quantitative
interpretation of toxic effects of compounds in in vitro studies, using
in silico approaches such as systems biological descriptions of toxicity
pathways and physiologically based pharmacokinetic modeling (PBPK),
are a necessary component of the National Academy of Sciences vision
on toxicity testing in the 21st Century. The limited studies performed with
this approach to date have shown that good predictions for the risk of the
use of chemicals can be made. However, a number of limitations have
also become clear and more standardization of methods is needed before
implementation of quantitative in vitro-in vivo extrapolations (QIVIVE) in
risk assessments can be achieved.
In this course, the following elements of the approach for assessing risks
on the basis of in vitro toxicity data will be discussed:
1. How can we improve the applicability of in vitro methods by determining
the real concentrations that come into contact with the cells
in vitro, both for chemical compounds and for particles?
2. How can we effectively and efficiently integrate the metabolism of
compounds, for clearance as well as for bioactivation?
3. How can we provide a flexible and yet robust scheme for integrating
the different elements in a high-throughput environment?
• The Use of In Vitro Metabolism Data and Biokinetic Modeling to
Conduct QIVIVE for Chemicals, Bastiaan Johan Blaauboer, Utrecht
University, Utrecht, Netherlands
• Characterizing Free Test Chemical Concentration during In
Vitro Toxicity Assays, Nynke Kramer, Utrecht University, Utrecht,
Netherlands
• Particokinetic Modeling to Support QIVIVE for Particle Toxicity
Assays, Justin G. Teeguarden, Pacific Northwest National Laboratory,
Richland, WA
• QIVIVE in a High-Throughput Environment, Harvey J. Clewell,
III, The Hamner Institutes for Health Sciences, Research Triangle
Park, NC
Sunday Afternoon, March 6
1:15 PM to 5:00 PM
First and Second Level (See signage at CE Booths for room
locations)
Novel Approaches to Preclinical Safety Assessment:
Bridging the Gap between Discovery and the Clinic through
Translational Toxicology
Stem Cell Utility in Toxicology Screening
PM14
CE Basic
Chairperson(s): Manu M. Sebastian, Columbia University, New York, NY,
and Zaher A. Radi, Pfizer Global Research and Development, Cambridge,
MA.
Sponsors:
Society for Toxicologic Pathology
Toxicologic and Exploratory Pathology Specialty Section
The development of toxicological screening tools for evaluating toxicity
of new drug candidates has been a major focus in the pharmaceutical
industry. Human embryonic stem (hESC) cells and induced pluripotent
stem (iPS) cells and their lineage cells can be used as tools to predict
developmental and other toxicities of drug candidates since several of
the human biochemical pathways are active in these cells. In addition,
stem cells can also be used to help in the mechanistic understanding of
how a specific class of compounds leads to toxicity. Participation in this
course will provide a basic overview of the utility of stem cells in drug
discovery and update toxicologists on a variety of stem cells applications
as screening tool for evaluating toxicity in multiple organ systems,
thereby giving toxicologists a better understanding of the potential practical
application of these in vitro methods for safety and risk assessment.
• Introduction: Stem Cells As Tools for Toxicology Screening, Manu
M. Sebastian, Columbia University, New York, NY
• Metabolomics of Human Embryonic Stem Cells and Predictive
Biomarkers of Developmental Toxicity, Gabriela Cezar, University
of Wisconsin, Madison, WI
• Stem Cells and Mice with Humanized Livers: New Tools for Drug
Metabolism and Toxicology, Stephen Strom, University of Pittsburgh
Medical School, Pittsburgh, PA
• Using Embryonic Stem Cell Models to Profile Potential
Developmental Toxicants, E. Sidney Hunter III, U.S. EPA, Research
Triangle Park, NC
• Stem Cells in Preclinical Drug Development, Hirdesh Uppal,
Genentech, Inc., South San Francisco, CA
• Concluding Remarks, Zaher A. Radi, Pfizer Global Research and
Development, Cambridge, MA
CE
up-to-date information at www.toxicology.org
95